The joint venture, Paradigm, is being formed under the Michigan Health Corporation, an arm of UMHS that enables outside partnerships. Paradigm will offer whole gene and multi-gene sequencing and molecular diagnostics to providers across the country and will also help support various clinical trials.
“Pursuing new, innovative channels for scientific collaboration is a priority and strength of the University of Michigan,” said Ora Pescovitz, MD, CEO of the U-M Health System and U-M executive vice president for medical affairs, in a statement. “Paradigm is a terrific example of this effort and of how cutting-edge science will have an immediate benefit for patients.”
More Articles on University of Michigan Health System:
University of Michigan Health Launches New Oncology Research Program
University of Michigan Health Program Reduces Readmissions
University of Michigan Health Adds 14 Cardiologists to Meet Outpatient Demand
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
